1-6 of 6
Eva Schmidt
Close
Sort by
Journal Articles

Treatment of MDS, AML and CMML Relapse after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions - Final Results of the Prospective Azalena-Trial (NCT02472691)

Thomas Schroeder, Matthias Stelljes, Maximilian Christopeit, Eva Schmidt, Christoph Scheid, Jan-Henrik Mikesch, Christina Rautenberg, Paul Jäger, Nadja Drusenheimer, Udo Holtick, Stefan Klein, Rudolf Trenschel, Rainer Haas, Ulrich Germing, Nicolaus Kröger, Guido Kobbe
Journal: Blood
Blood (2021) 138 (Supplement 1): 411.
https://doi.org/10.1182/blood-2021-153282
Published: 2021
Journal Articles

Treatment of MDS, AML and CMML Relapse after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions Results from the Second Interim Analysis of the Prospective Azalena-Trial (NCT02472691)

Thomas Michael Schroeder, MD PhD, Christina Rautenberg, MD, Max Christopeit, Matthias Stelljes, MD, Eva Schmidt, Christoph Groth, MD, Christoph Scheid, MD, Udo Holtick, MD PhD, Stefan A Klein, MD, Dietrich W. Beelen, Kathrin Nachtkamp, MD, Rainer Haas, MD, Ulrich Germing, MD, Nicolaus Kröger, MD, Guido Kobbe
Journal: Blood
Blood (2018) 132 (Supplement 1): 703.
https://doi.org/10.1182/blood-2018-99-113776
Published: 2018
Journal Articles

High-Dose Melphalan-Based Sequential Conditioning Chemotherapy Followed By Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Christoph Groth, MD, Nina Kristin Steckel, MD, Jan-Henrik Mikesch, Rudolf Trenschel, MD, Hellmut Dietmar Ottinger, MD PhD, Carsten Müller-Tidow, Christoph Schliemann, Christian Reicherts, Eva Schmidt, Wolfgang E. Berdel, Georg Lenz, Markus Ditschkowski, Dietrich W Beelen, MD PhD, Matthias Stelljes, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3205.
https://doi.org/10.1182/blood.V130.Suppl_1.3205.3205
Published: 2017
Journal Articles

Treatment of Relapse of MDS, AML and CMML after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions - Results from the First Interim Analysis of the Azalena-Trial (NCT02472691)

Thomas Schroeder, MD, Christina Rautenberg, MD, Max Christopeit, Matthias Stelljes, MD, Eva Schmidt, Stefan Klein, MD, Christof Scheid, MD, Dietrich W Beelen, MD PhD, Kathrin Nachtkamp, MD, Rainer Haas, MD, Ulrich Germing, MD, Nicolaus Kröger, Guido Kobbe, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4521.
https://doi.org/10.1182/blood.V130.Suppl_1.4521.4521
Published: 2017
Journal Articles

Identification of Lats 1 As a Putative Tumor Suppressor in HoxA9/Meis Induced Leukemia

Eva Schmidt, MD, Jana Krosl, PhD, Jalila Chagraoui, PhD, Nadine Mayotte, Caroline Pabst, MD, Tara McRae, Guy Sauvageau, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 2474.
https://doi.org/10.1182/blood.V118.21.2474.2474
Published: 2011
Journal Articles

Use of Palifermin for the Prevention of High-Dose Methotrexate-Induced Oral Mucositis.

Eva Schmidt, MD, Nils H. Thoennissen, M.D., Annika Rudat, M.D., Ralf Bieker, M.D., Christoph Schliemann, M.D., Rolf M. Mesters, M.D., Michael Zühlsdorf, M.D., Carsten Müller-Tidow, M.D., Wolfgang E. Berdel, M.D.
Journal: Blood
Blood (2007) 110 (11): 4445.
https://doi.org/10.1182/blood.V110.11.4445.4445
Published: 2007